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Abstract: Although the cerebellum is generally thought of as an area spared of Alzheimer’s disease (AD) pathology,
recent evidence suggests that balance and mobility dysfunction may be magnified in affected individuals. In the
present study, we sought to determine the degree of pathological changes within the cerebellum utilizing an antibody that specifically detects caspase-cleaved GFAP within degenerating astrocytes. Compared to control subjects,
application of this antibody, termed the GFAP caspase-cleavage product (GFAPccp) antibody, revealed widespread
labeling in cerebellar white matter with little staining observed in grey matter. Staining was observed within damaged astrocytes, was often localized near blood vessels and co-localized with other markers of apoptosis including
TUNEL and caspase-cleaved tau. Of interest was the association of beta-amyloid deposition in white matter together
with GFAPccp in cerebellar AD sections. In contrast, utilizing the tangle marker, PHF-1, neuritic pathology was completely absent in AD cerebellar sections. It is suggested that the observed pathological changes found in the white
matter of the cerebellum may contribute to the declined motor performance in AD.
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Introduction
The cerebellum is a subcortical brain structure
that is essential for learning and controlling
movement [1]. The cerebellum does not initiate
movement, but it contributes to the proper timing, coordination, and fine-tuning precision of
movement [2]. Consequently, lesions in the cerebellum may lead to postural instability, loss of
balance and of normal gait [3]. While Alzheimer’s
disease (AD) is characterized by the extent of
plaques and tangles predominantly within the
hippocampus and cortex, the cerebellum is
thought to be largely spared of pathology and is
often used as an area of comparison (for example see, [4, 5]). In this regard, studies in AD
have documented the relative lack of neuropathological changes in the cerebellum including the integrity of granule cell number and
density [6]. However, several studies have indicated that despite the absence of tau pathology [7, 8], it is not uncommon to find diffuse amy-

loid deposits both in the granular cell layer as
well as in white matter of the cerebellum of AD
subjects [9-11].
In spite of the relative lack of pathology associated with the cerebellum, several studies have
documented mobility dysfunction, loss of balance, and an increase risk for falls in Alzheimer’s
patients as compared to nondemented controls
[12-16]. The motor impairments, including gait
and balance dysfunctions in AD might suggest
that pathological changes are evident in this
structure that may occur independently of neuritic changes due to the lack of neuropathology
found in the cerebellum. To examine this possibility, we tested for the presence of white matter changes utilizing an antibody (GFAPccp) that
specifically detects caspase-cleaved GFAP
within degenerating astrocytes of the AD brain
[17-19]. Using this antibody, we now document
the labeling of damaged astrocytes along blood
vessels in cerebellar white matter of AD sub-

Caspase-cleaved GFAP in cerebellar white matter of the AD brain
jects. Moreover, there was a clear association
in the pattern of labeling of the GFAPccp antibody with beta-amyloid deposition suggesting
a potential interaction between astrocytes and
deposited beta-amyloid. The presence of pathological white matter changes within the cerebellum may contribute to the gait and balance
abnormalities associated with AD.
Materials and methods
Antibody dilutions
The rabbit GFAPccp (in house, 1:100). The anti
beta-amyloid mAb 1560 clone 6E10 (1:400),
and PHF-1 (mouse monoclonal, 1:1000). The
mAb TauC3 (caspase-cleaved tau) was utilized
at 1:100. To visualize beta-amyloid staining,
sections were pretreated for 5 minutes in 95%
formic acid. To assess apoptosis, the Apoptag
peroxidase kit was employed according the
manufacturer’s instructions (Millipore).

label was visualized using the Blue SG substrate (Vector Labs).
Immunofluorescence microscopy
Immunofluorescence studies were performed
by incubating sections with primary antibody
overnight at a room temperature, followed by
secondary anti-rabbit or mouse biotinylated
anti-IgG (1 hour) and then in ABC (1 hour).
Visualization was accomplished by using a tyramide signal amplification kit (Molecular Probes,
Eugene, OR) consisting of Alexa Fluor
488-labeled tyramide (green, Ex/Em =
495/519). For immunofluorescence co-localization studies, antigen visualization was
accomplished using an Alexa fluor 488-labeled
tyramide (green, Ex/Em = 495/519) for one
label and streptavidin Alexa fluor 555 (red, Ex/
Em = 555/565) for the second label, both from
Invitrogen (Carlsbad, CA).

Immunohistochemistry

Results

Autopsy cerebellum brain tissue from five neuropathologically confirmed AD cases and five
neuropathologically normal cases were studied. Human brain tissue sections used in this
study was provided by the Institute for Memory
Impairments and Neurological Disorders at the
University of California, Irvine. Free-floating 50
μm-thick sections were used for immunohistochemical studies as previously described [20].
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For single labeling, all sections were washed
with 0.1 M Tris-buffered saline (TBS), pH 7.4,
and then pretreated with 3% hydrogen peroxide
in 10% methanol to block endogenous peroxidase activity. Sections were subsequently
washed in TBS with 0.1% Triton X-100 (TBS-A)
and then blocked for thirty minutes in TBS-A
with 3% bovine serum albumin (TBS-B).
Sections were further incubated overnight at
room temperature in various primary antibodies as listed above. Following two washes with
TBS-A and a wash in TBS-B, sections were incubated in anti-rabbit or mouse biotinylated antiIgG (1 hour) and then in avidin biotin complex (1
hour) (ABC, Elite Immunoperoxidase, Vector
Laboratories, Burlingame, CA, USA). Antibodies
were visualized using Brown DAB substrate
(Vector Laboratories). For bright-field immunohistochemical double labeling, primary antibody labeling was detected using the brown
DAB substrate (Vector Labs), while the second
42

As an initial approach, we screened cerebellum
tissue sections from AD subjects or agematched controls utilizing our in house GFAPccp
antibody that detects caspase-cleaved GFAP
within
degenerating
astrocytes
[17].
Immunohistochemical analysis revealed widespread labeling of the GFAPccp antibody principally within white matter of AD cerebellum tissue sections (Figure 1A). In contrast, we
observed very little staining of the GFAPccp
antibody in age-matched control sections in
either white or gray matter of the cerebellum
(Figure 1B). Closer examination of the GFAPccp
labeling in AD sections indicated strong staining of damaged astrocytes that were in close
proximity to blood vessels. This type of staining
was very similar to previous results that we
found in hippocampal regions of the AD brain
[17].
The GFAPccp antibody colocalizes with other
markers of apoptosis
To confirm that labeling in cerebellar white matter of the GFAPccp antibody was occurring in
astrocytes undergoing apoptosis, double-label
experiments were performed using two additional markers for apoptosis including TUNEL
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Figure 1. Caspase-cleaved GFAP in cerebellar white matter of the AD brain. A: Representative labeling in the cerebellum of an AD case at low magnification utilizing the GFAPccp antibody indicated widespread labeling primarily in
white but not gray matter. B: Representative labeling in a control case with the GFAPccp antibody revealed a relative
absence of labeling in both white and gray areas of the cerebellum. C and D: High magnification of staining with the
GFAPccp antibody in representative AD cases indicating labeling of degenerating astrocytes along blood vessels in
the white matter of the cerebellum (arrows, C and D). Scale bars are: A, 100 µm; B, 300µm; C and D, 10 µm.

and caspase-cleaved tau. Using TUNEL labeling, we confirmed both by bright field and immunofluorescence the colocalization with GFAPccp
within astrocytes in cerebellar white matter of
the AD brain (Figure 2A and 2B). Additional
experiments were carried out using an antibody
that selectively detects caspase-cleaved tau.
This antibody, termed TauC3 recognizes the
C-terminal cleavage fragment of tau following
cleavage at D421 and has been used as a
marker for the activation of apoptosis in the AD
brain [21]. Double-label immunofluorescence
experiments utilizing GFAPccp together with
the TauC3 antibody indicated strong colocalization between the two markers (Figure 2C).
Double labeling appeared to be confined to a
large extent within damaged astrocytes along
blood vessels in cerebellar white matter (Figure
2C).
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Association between beta-amyloid deposition
and GFAPccp in cerebellar white matter of the
AD brain
Experiments were performed to determine any
possible relationship between the presence of
caspase-cleaved GFAP with pathological features of AD including beta-amyloid deposition
and neuritic pathology. Staining of cerebellum
sections with anti beta-amyloid mAb 1560
clone 6E10 revealed diffuse, punctate betaamyloid deposition predominantly within white
but not gray matter of the AD brain (Figure 3A
and 3B). The diffuse pattern of labeling was in
contrast to staining of beta-amyloid in AD frontal cortex sections that led to the characteristic
labeling of senile plaques containing a welldefined core (Figure 3C). To identify a possible
association between beta-amyloid deposition
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Figure 2. Colocalization of the GFAPccp antibody with markers of apoptosis in the cerebellum of the AD brain. A: Representative bright field microscopy image from the cerebellum of AD brain sections utilizing the GFAPccp antibody
(blue) together with TUNEL labeling (brown) revealed labeling of apoptotic nuclei within degenerating astrocytes
(arrows, A). The arrowhead in Panel A represents TUNEL labeling in the absence of GFAPccp staining. B: Confirmation of colocalization in Panel A was confirmed following double-label immunofluorescence imaging, with GFAPccp
fluorescence (red), TUNEL fluorescence (green), and where the two markers colocalized (yellow). C: Double-label immunofluorescence merged image utilizing an antibody to caspase-cleaved tau (red) and GFAPccp (green). The data
indicated colocalization between the two markers along a blood vessel in white matter of the cerebellum (yellow).
All scale bars represent 10µm.

and GFAPccp, double-labeling experiments
were performed. In this case, the two markers
often appeared localized within the same areas
of white matter in the cerebellum (Figure 3D).
In this regard, we often found damaged astrocytes labeled with GFAPccp that were in close
proximity to diffuse plaques (arrowhead, Figure
3D). In addition, GFAPccp-labeled astrocytes
appeared to exhibit punctate beta-amyloid
labeling upon their surface (arrows, Figure 3D).
In contrast to the diffuse beta-amyloid deposition, we could find no evidence of any neuritic
changes as indicated by the complete absence
of PHF-1 labeling in the cerebellum of AD sub44

jects (Figure 3E). As a positive control, we performed side-by-side staining of AD frontal cortex sections with PHF-1, leading to the extensive
staining of NFTs and neuropil threads as
expected (Figure 3F).
Discussion
Although the major symptoms associated with
AD are cognitive in nature, emerging data suggests that motor dysfunction is an important
component to the disease process. Thus,
recent studies have documented gait and balance impairments as well as an increase risk
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Figure 3. Association of GFAPccp with beta-amyloid deposition within white matter of the cerebellum in the AD brain.
A-B: Representative labeling with anti-Ab antibody, clone 6E10 at low (A) and high (B) magnification in representative cerebellum AD brain sections indicated diffuse staining predominately within white matter (left half of Panel
A). Scale bars represent 20 µm in Panel A and 10 µm in Panel B. C: Illustrates comparison staining with the same
antibody utilizing frontal cortex AD sections revealing labeling of amyloid plaques with a central core. D: Doubleimmunofluorescence labeling in the cerebellum of a representative AD case utilizing anti-Ab antibody, clone 6E10
(red) and GFAPccp antibody (green) indicated a close association between the two markers within white matter.
Arrows in Panel D represent putative degenerated astrocytes while arrowhead in same panel designates a diffuse
plaque. Scale bars in Panels C and D are equivalent to 10 µm. E and F: Representative staining of the AD brain using
the tangle marker, PHF-1 in cerebellum (E) and frontal cortex (F) indicated a complete lack of neuritic pathology in
the cerebellum as compared to frontal cortex. Scale bars in Panels E and F represent 20µm.

for falls [12-16]. Because of the predominant
role that the cerebellum plays in providing for
precise timing for coordinated movement, a
likely hypothesis for explaining motor dysfunction in AD is some underlying dysfunction in this
brain structure. However, the cerebellum has
the distinction of being spared from the classic
pathology of AD, namely plaques and tangles
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and because of this is often used as control
region for comparison purposes (for example
see, [4, 5]). Several studies have documented
the presence of beta-amyloid deposition in the
cerebellum [9-11] but there is very little evidence for any neuropathological changes
including the presence of NFTs [7, 8]. The purpose of the present study was to examine the
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cerebellum in AD for other pathological features in addition to beta-amyloid and NFTs.
Numerous studies have suggested the activation of apoptotic pathways in the AD brain. In
this regard, the activation of caspases and
cleavage of critical proteins including betaamyloid, tau, fodrin, and GFAP may promote the
underlying pathology associated with AD (for
review see [22]). To date, whether the activation of apoptotic pathways occurs in the cerebellum has not been investigated. Therefore,
we examined cerebellar AD brain sections
employing a custom-made, in house antibody
(GFAPccp) that specifically detects caspasecleaved GFAP within degenerating astrocytes
[17-19]. Application of GFAPccp revealed widespread labeling in white matter of cerebellar AD
sections, while little staining was noted in agematched control sections. Specifically, GFAPccp
labeled damaged astrocytes in white matter
that were often localized near blood vessels.
The morphological appearance of GFAPccplabeled astrocytes suggested that these cells
were severely damaged and exhibited characteristics of apoptosis. These results mirrored
our previous findings with the GFAPccp antibody in AD hippocampal sections [17]. One
important role of astrocytes is in the formation
of the blood-brain barrier and in this role, astrocytes confer a protective role against hypoxia
and aglycemia by extending end feet that
encapsulate brain capillaries [23]. Our current
results suggest that activation of apoptotic
pathways and cleavage of cytoskeletal proteins, such as GFAP and tau, may be one of
many factors that contribute to the compromised blood-brain barrier observed in AD
[24-27].
Another finding of the present study was the
apparent association between beta-amyloid
deposition and caspase-cleaved GFAP in cerebellar white matter. Diffuse beta-amyloid staining was observed in white matter but was rarely
found in gray matter of AD cerebellum sections.
Moreover, double-label immunofluorescence
experiments revealed punctate beta-amyloid
staining on GFAPccp-labeled astrocytes
(arrows, Figure 3D). We observed a similar relationship in AD hippocampal brain sections [17]
and taken together the results suggest that
astrocytes are activated and recruited to sites
of beta-amyloid deposition. Several studies
have now documented the important role that
astrocytes may play in clearing beta-amyloid
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via the ability to internalize deposited betaamyloid peptides [28, 29]. In the process of
clearing beta-amyloid, astrocytes themselves
may be subjected to beta-amyloid-induced toxicity leading to the activation of apoptosis and
eventual degeneration. Indeed, in a previous
report we documented the ability of beta-amyloid to induce apoptosis and caspase-cleavage
of GFAP in cultured astrocytes [17]. White matter labeling of degenerating astrocytes were
independent of any neuropathological changes
as evidenced by the complete lack of PHF-1
labeling in all regions of AD cerebellar tissue
sections (Figure 3E).
In conclusion, results from the present study
support the caspase cleavage of cytoskeletal
proteins including tau and GFAP within astrocytes in cerebellar white matter of the AD brain.
The cleavage of critical cytoskeletal proteins
may lead to the breakdown of the framework of
the astrocyte and contribute to astrocytic
degeneration along blood vessels. It is suggested that these events may be initiated in astrocytes following their interaction with deposited
beta-amyloid in white matter of the cerebellum.
Although the cerebellum has historically been
defined as a brain structure largely spared from
AD pathology, recent clinical evidence indicating an increase risk for falls and impairment of
gait and balance suggest otherwise. Our results
provide a potential molecular mechanism
involving astrocyte degeneration and disruption of the blood brain barrier in cerebellar
white matter as a putative contributing factor
to mobility impairments associated with AD.
Abbreviations
AD, Alzheimer’s disease; Aβ, beta amyloid; CCP,
caspase-cleavage product; GFAP, glial acidic
fibrillary protein; NFTs, neurofibrillary tangles;
PHF, paired helical filaments; TBS, tris-buffered
saline.
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